The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related breathing disorder that is most common in people who are overweight and ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The U.S. Food and Drug Administration approved Zepbound for patients with obesity and mild to moderate obstructive sleep apnea on Dec. 20, making it the first approved treatment for the roughly 20 ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

For people with both moderate-to-severe sleep apnea and obesity, the FDA-approved prescription medication Zepbound (tirzepatide) may help reduce body weight and, in turn, improve breathing.

Zepbound is the first FDA-approved medication for OSA. A doctor may also consider other treatments that help address underlying causes of sleep apnea to help reduce your symptoms. These can ...

UAE -- The U.S. Food and Drug Administration (FDA) approved lately Tirzepatide, produced by Eli Lilly, as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep ...